Holen Sie sich die Stockscreener-App
41.01
0.34%
0.14
Handel nachbörslich:
40.81
-0.20
-0.49%
Schlusskurs vom Vortag:
$40.87
Offen:
$41.18
24-Stunden-Volumen:
8.33M
Relative Volume:
0.71
Marktkapitalisierung:
$16.02B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-4.6976
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-6.94%
1M Leistung:
+15.00%
6M Leistung:
+53.54%
1J Leistung:
+22.02%
1-Tages-Spanne:
$39.50
$41.49
1-Wochen-Bereich:
$39.50
$46.58
52-Wochen-Spanne:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
41.01 | 15.97B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
A Double Blow for Moderna – Seqirus Topples Two mRNA Patent Applications - Pearce IP
1 Stock to Buy, 1 Stock to Sell This Week: Cisco, Moderna - Investing.com Nigeria
United StatesGoodwin Advises Moderna On Strategic Collaboration With Recordati To Globally Commercialize Investigational Propionic Acidemia Therapeutic (MRNA-3927) For $50 Million Upfront And Up To $110 Million In - Mondaq
Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline - GuruFocus
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Moderna faces $5 billion mRNA patent lawsuit after ‘Star Trek’ ruling - thestreet.com
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock - Yahoo Finance
Moderna (MRNA) to Release Quarterly Earnings on Friday - MarketBeat
Morgan Lewis Hires Moderna In-House Pro In Munich - Law360
Defiance adds single stock ETFs tied to Zeta Global, Moderna - Structured Retail Products
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Judge Wolson Issues Key Summary Judgment Ruling on the Eve of Trial in the Arbutus v. Moderna mRNA Vaccine and Lipid Nanoparticle Case - JD Supra
The Escalator: Moderna, Sparrow Pharmaceuticals, Takeda and more - Medical Marketing and Media
Analysts Offer Insights on Healthcare Companies: Merck KGaA (GB:0O14) and Moderna (MRNA) - The Globe and Mail
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider - GlobeNewswire Inc.
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Judge Wolson Issues Key Summary Judgment Ruling on Eve of Trial in Arbutus v. Moderna - IPWatchdog.com
Jim Cramer on Moderna: "Even Though the Stock's on the Mend, There Are Many Pharma and Biotech Names That I Like Better" - Finviz
Jim Cramer on Moderna: “Even Though the Stock’s on the Mend, There Are Many Pharma and Biotech Names That I Like Better” - Insider Monkey
Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda - Fox Business
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. - Investing News Network
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna's 7-Step Guide to Veeva AI for PromoMats - Veeva
Why The Narrative Around Moderna (MRNA) Is Shifting After Mixed Analyst Updates - Yahoo Finance
Moderna Refocuses On Rare Disease Pipeline As Leadership Evolves - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Are Wall Street Analysts Bullish on Moderna Stock? - Barchart.com
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Shreveport Times
How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks - Yahoo Finance
BioNTech Expands Beyond mRNA While Moderna Focuses on mRNA Pipeline Post-Pandemic - geneonline.com
'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit - Law360
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Moderna (MRNA) Sees Moderate Bearish Activity Amid Upcoming Earnings - GuruFocus
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Jim Cramer on Moderna: “We have to wait and see” - MSN
Spotlight on Moderna: Analyzing the Surge in Options Activity - Benzinga
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43% - simplywall.st
Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline - Yahoo Finance
Is Moderna (MRNA) Pricing Fair After Recent 42.8% Monthly Share Price Jump - Yahoo Finance
Gainers Report: Can Moderna Inc continue delivering strong returnsIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Moderna Stock Slips As Ambitious Cancer Trials Drag On - TipRanks
91,010 Shares in Moderna, Inc. $MRNA Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Privium Fund Management B.V. Lowers Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna appoints David Berman as new chief development officer By Investing.com - Investing.com South Africa
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates - Treasure Coast News
Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift - GuruFocus
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):